Dominic Schiller - Alterola Biotech Chief Counsel
| ABTI Stock | USD 0 0.0001 2.44% |
Insider
Dominic Schiller is Chief Counsel of Alterola Biotech
| Age | 58 |
| Phone | 44 1516 019 477 |
| Web | https://alterola-abti.com |
Alterola Biotech Management Efficiency
The company has return on total asset (ROA) of (0.6669) % which means that it has lost $0.6669 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2729) %, meaning that it created substantial loss on money invested by shareholders. Alterola Biotech's management efficiency ratios could be used to measure how well Alterola Biotech manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 2 records | INSIDER Age | ||
| Francois Lafortune | Crescita Therapeutics | N/A | |
| Dominic KingSmith | Crescita Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.27 | |||
| Return On Asset | -0.67 |
Alterola Biotech Leadership Team
Elected by the shareholders, the Alterola Biotech's board of directors comprises two types of representatives: Alterola Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alterola. The board's role is to monitor Alterola Biotech's management team and ensure that shareholders' interests are well served. Alterola Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alterola Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Colin BSc, COO Director | ||
| Timothy Rogers, Ex CFO | ||
| Seamus McAuley, S Director | ||
| David OBE, CEO Director | ||
| Hunter Land, VP Director | ||
| Dominic Schiller, Chief Counsel |
Alterola Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Alterola Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.27 | |||
| Return On Asset | -0.67 | |||
| Current Valuation | 68.08 M | |||
| Shares Outstanding | 807.05 M | |||
| Price To Book | 6.29 X | |||
| EBITDA | (6.47 M) | |||
| Net Income | (6.47 M) | |||
| Cash And Equivalents | 61.54 K | |||
| Total Debt | 251.18 K | |||
| Debt To Equity | 0.02 % |
Currently Active Assets on Macroaxis
Other Information on Investing in Alterola Pink Sheet
Alterola Biotech financial ratios help investors to determine whether Alterola Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterola with respect to the benefits of owning Alterola Biotech security.